Clinical trial
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
NCT00442832 · Theravance Biopharma, Industry · Completed
Key facts
| NCT number | NCT00442832 |
|---|---|
| Title | TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection |
| Official title | A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections |
| Lead sponsor | Theravance Biopharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Staphylococcal Skin Infection |
| Intervention type | Drug |
| Interventions | TD-1792, Vancomycin |
| Enrollment | 203 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Mar 2, 2007 |
| Last update posted | Jan 20, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: